The electronic Common Technical Document has been the global standard for pharma dossier management for over two decades. Most organisations built their workflows around eCTD 3.2.2 and moved on. In 2026, three developments are forcing
Read More
If you have ever sat across a regulatory team trying to prepare simultaneous dossiers for the US FDA, EMA, and CDSCO, you already know the feeling. It is not just about assembling data. It is
Read More
MOH interaction and health authority liaison have become critical differentiators for medical device manufacturers navigating diverse, regulated, and fast-evolving regulatory landscapes. Every country’s Ministry of Health (MOH) or equivalent health agency expects precise documentation, consistent
Read MoreIdeating, researching, and developing a drug or biologic product and bringing it to market is not a simple process. From preclinical discovery through market authorization, every stage of the drug lifecycle is critical. Across the
Read More
Are you a medical device manufacturer working on digital therapeutics, remote monitoring tools, or AI-enabled care solutions for chronic disease management? If your innovation is outcome-based and driven by real-world data, you should pay close
Read MoreDo you have authorization to conduct a clinical trial with your investigational drug? Do you know that you should evaluate the safety data and analyse the emerging risks during trials? During the clinical development of
Read MoreIn the European Union (EU), rare diseases contribute to approximately 6-8% of total deaths across all age groups. The death percentage is about 35% among the pediatric population, especially in the first year of life,
Read More
Pharmacovigilance 2026 is set to be a definitive platform for patient safety, featuring strengthened and automated vigilance systems. The future of Pharmacovigilance is poised for a transformative shift, driven by new avenues such as automation
Read More
 An Asia-based mid-sized pharmaceutical company sought to launch a generic anti-hypertensive drug in the U.S. market. With limited internal expertise in FDA submissions and facing a tight launch timeline, the client needed end-to-end support for
Read MoreA global medical device manufacturer needed to expand into multiple new markets across Europe, Middle East, and Asia-Pacific (EMEA & APAC). The challenge was to achieve quick and compliant registration of Class II and III
Read More